



Post-herpetic encephalitis cerebral abscess: Viral reactivation or latency site within central nervous system?

Mélanie Catroux, Magali Garcia, Nicolas Lévêque, Philippe Page, Gwenael Le Moal, David Boutolleau, France Roblot, Sonia Burrel

► To cite this version:

Mélanie Catroux, Magali Garcia, Nicolas Lévêque, Philippe Page, Gwenael Le Moal, et al.. Post-herpetic encephalitis cerebral abscess: Viral reactivation or latency site within central nervous system?. Current Research in Translational Medicine, 2021, 69 (3), pp.103297. 10.1016/j.retram.2021.103297 . hal-03477793

HAL Id: hal-03477793

<https://hal.sorbonne-universite.fr/hal-03477793>

Submitted on 13 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Post-herpetic encephalitis cerebral abscess: viral reactivation or latency site within central nervous system?

Mélanie Catroux¹, Magali Garcia², Nicolas Lévêque², Philippe Page³, Gwenael Le Moal¹, David Boutolleau⁴, France Roblot¹, Sonia Burrel⁴

¹Tropical Infectious Diseases Department, Poitiers University Hospital, Poitiers, France

²Virology and Mycobacteriology Department, Poitiers University Hospital, Poitiers, France and EA 4331, LITEC, University of Poitiers, Poitiers, France

³Department of Neurosurgery, Poitiers University Hospital, Poitiers, France

⁴Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and AP-HP, University Hospital Pitié-Salpêtrière – Charles-Foix, National Reference Center for Herpesviruses, Virology Department, Paris, France

melanie.catroux@chu-poitiers.fr; magali.garcia@chu-poitiers.fr; nicolas.leveque@chu-poitiers.fr; philippe.page@chu-poitiers.fr; gwenael.le-moal@chu-poitiers.fr; david.boutolleau@aphp.fr; france.cazenave-roblot@chu-poitiers.fr; sonia.burrel@aphp.fr

Address for correspondence (corresponding author):

Pr Nicolas LEVEQUE, Virology and Mycobacteriology Department, Poitiers University Hospital, Poitiers, France and EA 4331, LITEC, University of Poitiers, Poitiers, France.

Email: nicolas.leveque@chu-poitiers.fr; Phone: +33 5 49 44 38 17

27 **Abstract**

28 Herpetic encephalitis results from central nervous system invasion by herpes simplex virus. We
29 report the case of a man who developed a cerebral abscess fifteen months after initial Herpetic
30 encephalitis. Retrospectively, antiviral should not have been associated with antibiotics during
31 abscess episode,as transcriptomic analysis reported no viral reactivation.

32

33 **Keywords:** herpes simplex virus; viral transcripts; herpetic encephalitis; cerebral abscess

Introduction

After oral primary infection, herpes simplex virus 1 (HSV-1) reaches trigeminal ganglia (TGs), and establishes latency in TGs but also in the central nervous system (CNS). During latency, viral latency-associated transcripts (LATs) are abundantly expressed, whereas viral lytic phase genes are severely silenced. Latent virus can reactivate and cause recurrent infection [1, 2]. During the lytic replicative phase, HSV-1 genes are expressed following a sequential cascade. First, immediate early (IE) genes are expressed straightaway upon viral DNA reaches the nucleus. Next, IE proteins promote the expression of early (E) genes implicated in viral DNA replication and stimulation of late (L) gene expression. L proteins are involved in capsid assembly and egress of mature virions. Herpes encephalitis (HE) results from CNS invasion by replicating HSV-1 following primary infection or, more commonly, reactivation within TGs or possibly CNS [3, 4]. HE results in acute brain inflammation possibly associated with hemorrhage, usually asymmetrically, in adult and most prominently with temporal lobe localization. Moreover, epilepsy crisis are frequently encountered during acute and post-acute phases of HE. In the course of HE, cerebrospinal fluid (CSF) abnormalities classically include around 100 white blood cells (WBC) per μL , with a predominance of lymphoid cells (75%-100%). Whereas protein CSF concentration may be normal or commonly be elevated, glucose CSF concentration remains at normal level. Mortality reaches 70% without the hasty set-up of antiviral therapy. Unfortunately, survivors may have severe persistent neurological deficits even with well-conducted therapy [5]. Typical complications of post-herpetic encephalitis do not include brain abscesses, which are classically due to bacterial infection in immunocompetent patients and are diagnosed on the basis of radiological and microbiological criteria. Performing blood cultures, neurosurgical stereotactic aspiration or drainage represent the more relevant ways to get samples allowing a microbiological documentation. An empiric antibiotherapy is then prescribed according to the clinical presentation as reviewed in [6]. For HE diagnosis, PCR techniques to amplify the HSV-1 DNA from CSF are considered as the gold standard with high sensitivity and specificity [5]. Acyclovir (ACV) constitutes the first-line therapy for the management of HE. ACV

requires activation by virus-encoded thymidine kinase (TK, UL23 gene) and targets viral DNA polymerase (UL30 gene) to disrupt viral genome replication by a chain termination mechanism. Alternative drug like foscarnet (FOS) directly inhibits the viral DNA polymerase. Mutations conferring antiviral resistance have been mapped both in UL23 and UL30 genes [7]. ACV resistance is rarely seen in HSV-1 HE however it should be considered in case of clinical worsening [8].

Case presentation

We report the case of a 64-year-old man who came for the removal of a cerebral abscess 15 months after an initial episode of HSV-1 HE. Positive HSV-1 PCR in the abscess and the CSF associated with neurological signs following surgery led to the suspicion of HE recurrence (Table 1). Retrospectively, we sought to determine whether HSV-1 transcription profiles in the abscess and the CSF were associated either with viral replication (i.e., HE relapse) or with viral latent state in CNS. Initially (day 0 of the first episode), the patient was admitted to hospital for altered mental status, fever and seizures leading to the clinical diagnosis of HE. After admission, he received broad antibiotic therapy and intravenous (IV) ACV. The CSF was turbid with a WBC of 210/ μ L (89% lymphocytes). Brain imaging revealed left sylvian hypodensity associated with vascular lesion. HSV-1 positive PCR in the CSF led to simplify the treatment with IV ACV as bacterial culture remained negative. In spite of anti-infectious treatments, the evolution was unfavorable on day 3 as new imaging showed diffuse cerebral edema. On day 10 of IV ACV, the patient presented with a clinical worsening with intracranial hypertension and coma, motivating his transfer to neurosurgical intensive care. The treatment was modified on day 21 to IV FOS because of persistent positive HSV-1 PCR in the CSF leading to a suspicion of viral ACV resistance. On day 27, the patient partly recovered under FOS and corticosteroids with, however, persistent neurological troubles. On day 31 (10 days of FOS), HSV-1 PCR was still positive in the CSF. Genotypic HSV-1 resistance were tested by Sanger sequencing of TK and DNA polymerase genes, as previously described [7]. Owing to the absence of resistance mutations within viral TK and DNA polymerase, IV ACV was reintroduced. An overall improvement in the clinical condition of the patient was progressively observed. IV ACV treatment

was discontinued after 2 months (day 60). The patient was followed in consultation at 9 months of discharge (day 270) and showed no signs of localization or neurological deficit.

The 1-year control magnetic resonance imaging (MRI) showed the appearance of a left temporal cystic image (day 360). Occurring of headaches and language problems led to cyst puncture after 15 months of the initial episode of HE. The patient had also seizures suppressed by anti-epileptic treatment. Cerebral abscess puncture fluid, which was purulent, was positive for HSV-1 by PCR and bacteria (*Propionibacterium* and *Staphylococcus capitis*) requiring adapted antibiotics. On day 4 post-operative (day 454 of initial HE episode), the patient presented meningitis symptoms and HSV-1 PCR was positive in the CSF. Cytological and biochemical analysis of the CSF showed WBC 137/ μ L (99% lymphocytes). The patient received IV ACV in addition to antibiotics. On day 8 of IV ACV (day 458), HSV-1 PCR in CSF was still positive. ACV was continued for 20 days (until day 478). No mutation associated with resistance to ACV was detected within HSV-1 genome present in the abscess and CSF during this second episode. HSV-1 PCR on day 14 and day 28 (day 464 and day 478 of initial HE episode, respectively) were negative. The patient was asymptomatic during all the 13-months period following period (last consultation on day 863).

In order to characterize the HSV-1 transcription profile in CSF and cerebral abscess sampled 15 months after initial episode of HSV-1 HE, total RNA was extracted from the clinical samples stored at -80°C and contaminating DNA was removed by DNase I digestion. Complementary DNAs were synthesized and then SYBR Green-based PCRs were performed targeting viral LATs and lytic genes. The published genomic sequence of HSV-1, strain 17 (GenBank accession number X14112) was used as template to design primer pairs for each viral transcript: ICP27 (IE gene), UL23 (TK, E gene), and UL19 (major capsid protein VP5, L gene). All primer sets were designed with uniform annealing temperatures to facilitate assessing multiple gene targets within the same PCR run. The specificity of each selected primer pairs was evaluated by melting curve analysis. Assay precision was determined using representative set genes from each HSV-1 transcriptional gene class to quantify viral transcript abundance in each sample. Viral gene transcripts were normalized to the cellular 18S ribosomal

RNA expression and relative fold change in gene expression for each specific viral gene was calculated by the $2^{-\Delta\Delta C_t}$ method [2]. Absence of residual DNA in purified RNA preparations was checked by PCR. The following controls were used: HSV-1-infected murine TGs (latent phase [kind gift from Pr M. Labetoulle and Dr A. Rousseau, Department of Ophthalmology, Bicêtre Hospital, APHP, Paris-Sud University, Le Kremlin Bicêtre, France]) and HSV-1-infected-Vero cells (lytic phase). Our results showed that LATs were detected neither in CSF nor cerebral abscess clinical samples. Thus, the cerebral abscess was not a viral latency site (Table 2). Concerning viral lytic transcripts, no significant signals were detected within these clinical samples suggesting that the virus was not replicating. The persistence of weak signals for IE and E genes (ICP27 and UL23 genes, respectively) was probably linked to previous replication process during the initial HE episode (Table 2).

Discussion

Numerous reports noted that there is a high percentage of the population with HSV-1 genetic material persisting in the CNS worldwide [9-12]. HSV-1 is known to use two contrasting infection strategies: replication (lytic gene expression) and latency (LATs expression). HSV-1 can periodically reactivate from latent state to resume replication and newly produce infectious progeny viruses resulting in virus transmission and recurrent disease [1]. Approximately two thirds of HE cases occur following reactivation from latency [3]. HSV DNA detection by PCR is commonly used for assessing the clinical significance of the infection. We report herein the case of a man who initially presented HE complicated by ischemic stroke, and then who was diagnosed a cerebral abscess 15 months later without HE symptoms. Virological investigations revealed HSV-1-positive PCRs in the CSF and in the abscess suggesting a relapse of HE. Nevertheless, relapse of HE are rare, occurring in 12 to 27% of cases, and, when they are late, related to auto-immune mechanisms through the production of antibodies against N-Methyl-d-aspartate receptor (NMDAR) rather than to viral reactivation leading to differential diagnosis in order to prove virus ongoing replication [13-16].

138 In the present work, we try to prove viral state in the abscess: replication or latency. Viral mRNA
139 detection may help the clinician to evaluate the need for initiating or stopping an antiviral therapy
140 since antivirals currently available are exclusively effective during the viral genome replication by
141 targeting the viral DNA polymerase [7]. Our results clearly showed that no viral replication was
142 ongoing in CNS during the second hospitalization. Moreover, the abscess was not identified as a
143 latency site. HSV-1 DNA detection was presumably due to viral genetic fragments embedded in
144 cerebral tissue over the first HE episode for upward of 15 months. Retrospectively, it appears that, in
145 the case described here, no antiviral should have been given in association with antibiotics to cure
146 the abscess. Our data suggest that transcriptomic assay could be used as a tool to monitor relapse, as
147 previously reported for cytomegalovirus (CMV)-related CNS disease. Indeed, the detection of a
148 specific viral mRNA, the CMV pp67 late gene transcript, in CSF has been proposed to complete PCR
149 testing assay [17]. This case-report highlights the need of further investigation for legitimacy of HSV
150 replication state characterization in order to optimize therapeutic management of such clinical
151 situations.

152 **Funding:**

153 This work was supported in part by the Association pour la Recherche sur les Infections Virales
154 (ARIV).

155

156 **Conflicts of Interest:**

157 The authors declare that they have no competing interests.

158

159 **Authors' Contributions:**

160 MC, PP, GLM, FR contributed to the diagnosis and treatment of the patient and reviewed the
161 manuscript. DB and SB carried out HSV-1 resistance research. SB performed HSV-1 transcriptomic
162 analyses and wrote the manuscript. MG and NL made the initial virological diagnosis and reviewed
163 the manuscript. All authors approved the final version of the manuscript.

164 **References**

- 165 1. Preston CM, Efstathiou S. Molecular basis of HSV latency and reactivation. In: Arvin A,
166 Campadelli-Fiume G, Mocarski E, et al., eds. Human Herpesviruses: Biology, Therapy, and
167 Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. p. 602-15.
- 168 2. Garvey CE, McGowin CL, Foster TP. Development and evaluation of SYBR Green-I based
169 quantitative PCR assays for herpes simplex virus type 1 whole transcriptome analysis. J Virol
170 Methods 2014;201:101-11.
- 171 3. Bradshaw MJ, Venkatesan A. Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology,
172 Diagnosis, and Management. Neurotherapeutics 2016;13:493-508.
- 173 4. Yao HW, Ling P, Tung YY, Hsu SM, Chen SH. In vivo reactivation of latent herpes simplex
174 virus 1 in mice can occur in the brain before occurring in the trigeminal ganglion. J Virol 2014.
175 88:11264-70.
- 176 5. Whitley R, Kimberlin DW, Prober CG. Pathogenesis and disease In: Arvin A, Campadelli-
177 Fiume G, Mocarski E, et al., eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.
178 Cambridge: Cambridge University Press; 2007. p. 589-601.
- 179 6. Cantiera M, Tattevin P, Sonnevile R. Brain abscess in immunocompetent adult patients. Rev
180 Neurol (Paris) 2019;175(7-8):469-74.
- 181 7. Burrell S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine
182 kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism
183 and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010;54:4833-
184 42.
- 185 8. Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E.M. Acyclovir resistance
186 in herpes simplex virus type I encephalitis: a case report. B J Neurovirol 2017;23:335-7.
- 187 9. Kennedy PG, Chaudhuri A. Herpes simplex encephalitis. J Neurol Neurosurg Psychiatry
188 2002;73:237-8.
- 189 10. Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem
190 multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996;2:249-58.
- 191 11. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's disease: the enemy
192 within. J Alzheimers Dis 2008;13(4):393-405.
- 193 12. Mori I, Kimura Y, Naiki H, Matsubara R, Takeuchi T, Yokochi T, Nishiyama Y. Reactivation of
194 HSV-1 in the brain of patients with familial Alzheimer's disease. J Med Virol 2004;73:605-11.
- 195 13. Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufríu
196 S, Muchart J, Erro ME, Abaira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejó C, Toledo
197 M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A,
198 Rosenfeld MR, Graus F, Dalmau J; Spanish Herpes Simplex Encephalitis Study Group. Frequency,
199 symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis:
200 a prospective observational study and retrospective analysis. Lancet Neurol 2018;17:760-72.

- 201 14. Dorcet G, Benaiteau M, Bost C, Mengelle C, Bonneville F, Martin-Blondel G, Pariente J. Two
202 Cases of Late-Onset Anti-NMDAr Auto-Immune Encephalitis After Herpes Simplex Virus 1
203 Encephalitis. *Front Neurol* 2020;11:38.
- 204 15. Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, Borowski K, Ahnert-Hilger G,
205 Harms L, Schwab JM, Ploner CJ, Komorowski L, Stoecker W, Dalmau J, Wandinger KP. *Ann Neurol*
206 2012;72(6):902-11.
- 207 16. Sköldenberg B, Aurelius E, Hjalmarsson A, Sabri F, Forsgren M, Andersson B, Linde A,
208 Strannegård O, Studahl M, Hagberg L, Rosengren L. Incidence and pathogenesis of clinical relapse
209 after herpes simplex encephalitis in adults. *J Neurol* 2006;253(2):163-70.
- 210 17. Zhang F, Tetali S, Wang XP, Kaplan MH, Cromme FV, Ginocchio CC. Detection of human
211 cytomegalovirus pp67 late gene transcripts in cerebrospinal fluid of human immunodeficiency virus
212 type 1-infected patients by nucleic acid sequence-based amplification. *J Clin Microbiol*
213 2000;38(5):1920-5.